SCHEMBL23923352

SCHEMBL23923352

CN(C(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 5/20 0.54
SLC6A5 Q9Y345 4/20 0.54
GPR139 Q6DWJ6 5/20 0.53
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ATM Q13315 1/20 0.47
PYGL P06737 2/20 0.46
AVPR1A P37288 1/20 0.45
TMEM97 Q5BJF2 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
RAB9A P51151 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CTSV O60911 1/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23923355 1.00 SLC6A9 (0.54) SLC6A9SLC6A5GPR139MEN1KMT2A
SCHEMBL23923394 0.92 GPR139 (0.51) SLC6A9SLC6A5GPR139KMT2APYGL
SCHEMBL23923396 0.92 GPR139 (0.51) SLC6A9SLC6A5GPR139KMT2APYGL
SCHEMBL23923365 0.91 GPR139 (0.54) SLC6A9SLC6A5GPR139MEN1KMT2A
SCHEMBL23923367 0.91 GPR139 (0.54) SLC6A9SLC6A5GPR139MEN1KMT2A
SCHEMBL23923341 0.90 KMT2A (0.47) SLC6A9GPR139KMT2AATMRAB9A
SCHEMBL23923343 0.90 KMT2A (0.47) SLC6A9GPR139KMT2AATMRAB9A
SCHEMBL23923326 0.89 SLC6A9 (0.51) SLC6A9SLC6A5GPR139PYGLTMEM97
SCHEMBL23923324 0.89 SLC6A9 (0.51) SLC6A9SLC6A5GPR139PYGLTMEM97
SCHEMBL23923553 0.84 GLA (0.51) GPR139PYGLTMEM97SIGMAR1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11850247-B2 Antiviral compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2023-12-26 US disclosed
US-20210322416-A1 ANTIVIRAL COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-10-21 US disclosed
US-20210322416-A1 ANTIVIRAL COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11850247-B2 Antiviral compounds ZC3HAV1, ZC3HAV1L, CD4 SLC6A9 2550/4885SLC6A5 2183/4885GPR139 2504/4885
US-20210322416-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, ZC3HAV1L, CD4 SLC6A9 2550/4885SLC6A5 2183/4885GPR139 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.